The Proportion of Randomized Controlled Trials That Inform Clinical Practice: A Longitudinal Cohort Study of Trials Registered on ClinicalTrials.gov

Nora Hutchinson<sup>1</sup> M.D., C.M., MPhil, Hannah Moyer<sup>1</sup> BSc, Deborah A. Zarin<sup>2</sup> MD, Jonathan Kimmelman<sup>1\*</sup> PhD

- 1. Studies of Translation, Ethics and Medicine (STREAM), Biomedical Ethics Unit, McGill University, Montreal, Quebec
- 2. Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, Cambridge, Massachusetts
- \*Corresponding Author: 15
- 16 Dr. Jonathan Kimmelman
- School of Population and Global Health, McGill University 17
- 2001 McGill College Avenue, Montreal QC H3A 1G1 18
- 19 Canada

1

2 3 4

5

6 7 8

9

10 11

12

13 14

20

23

25

- 21 Telephone: 514-398-3306
- 22 Email: jonathan.kimmelman@mcgill.ca
- 24 Word Count: 3031 words
- Conflicts of Interest: JK received consulting fees from Amylyx Inc. Authors declare no 26 other potential conflicts of interest. 27

#### Abstract

#### Background

- Prior studies suggest that clinical trials are often hampered by problems in design, conduct and reporting that limit their uptake in clinical practice. We have described "informativeness" as the ability of a trial to guide clinical, policy or research decisions.
- Little is known about the proportion of initiated trials that inform clinical practice.

#### Methods

We created a cohort of randomized interventional clinical trials in three disease areas (ischemic heart disease, diabetes mellitus and lung cancer), that were initiated between 1 January 2009 and 31 December 2010 using ClinicalTrials.gov. We restricted inclusion to trials aimed at answering a clinical question related to the treatment or prevention of disease. Our primary outcome was the proportion of clinical trials fulfilling four conditions of informativeness: importance of the clinical question, trial design, feasibility, and reporting of results.

#### Results

Our study included 125 clinical trials. The proportion meeting four conditions for informativeness was 26.4% (95% CI 18.9-35.0). Sixty-seven percent of participants were enrolled in informative trials. The proportion of informative trials did not differ significantly between our three disease areas.

#### Conclusions

Our results suggest that the majority of clinical trials designed to guide clinical practice possess features that may compromise their ability to do so. This highlights opportunities to improve the scientific vetting of clinical research.

#### Funding

This study was funded by the Fonds de recherche Santé Québec postdoctoral research grant (NH). This funding body was not involved in study design, conduct or reporting.

#### Introduction

The ultimate goal of clinical research is to produce evidence that supports clinical and policy decisions. Numerous analyses suggest that a substantial proportion of clinical trials aimed at informing clinical practice are marred by flaws in design, execution, analysis and reporting.<sup>1-8</sup> The initial research response to COVID-19 illustrated the fact that existing oversight mechanisms fail to prevent the initiation of flawed trials.<sup>9</sup> While unexpected events can stymie well-conceived and implemented studies, trials that have features rendering them unlikely to inform clinical practice may do harm by misleading potential participants of their benefits, and by diverting patient-participants from otherwise informative research efforts.<sup>10</sup>

We have previously described five conditions that trials should fulfill to support clinical or policy decision-making. <sup>10,11</sup> First, trials must ask an important and clinically relevant question that is not yet resolved. Second, trials must be designed to provide a meaningful answer to that question. Third, trials must be feasible, with achievable enrollment goals and timely primary outcome completion. Fourth, outcomes must be analyzed in ways that support valid interpretation. Last, trial results must be made accessible in a timely fashion.

In what follows, we created surrogate measures for four conditions of informativeness: trial importance, design quality, feasibility, and reporting (the fifth condition, analytical integrity, did not lend itself to objective, dichotomous assessment, and is not assessed below). We then evaluated the proportion of "clinically directed randomized controlled trials" in three common disease areas meeting these four

conditions. This information can be used to help healthcare and research systems identify studies in need of further scrutiny, thereby improving the impact of their research.

#### Methods

#### Overview of Approach

We created a cohort of randomized, interventional clinical trials in three broad disease areas that are representative of the clinical research enterprise and that have a significant impact on patient morbidity and mortality: ischemic heart disease, diabetes mellitus and lung cancer. We restricted inclusion to trials that appeared to be aimed at informing clinical practice by selecting trials with a stated purpose of treatment or prevention of disease and with a primary clinical outcome or appropriate surrogate. We established milestones that could serve as objectively verifiable surrogates for four conditions of informativeness. Trials in our sample were then tracked forward to assess the proportion attaining each informativeness condition. "Informative trials" were trials that fulfilled all four conditions of informativeness.

#### Surrogate Measures for Four Conditions of Informativeness

We formulated surrogate measures for each condition of informativeness.

Measures were chosen based on i) close correspondence with each informativeness condition; ii) objective and reproducible dichotomous scoring; and iii) feasibility of assessment. The four surrogates of informativeness, described in greater detail below,

were as follows: trial importance (determined by citation of reported trial results in high quality clinical synthesizing documents; the premise of this surrogate is that these documents focus on questions of clinical importance); trial design quality (assessed using a modified Cochrane risk of bias (ROB) tool which is designed to identify threats to study internal validity); trial feasibility (established based on ability to achieve adequate participant enrollment and timely primary outcome completion); and reporting (based on accessibility of primary outcome results via deposition on ClinicalTrials.gov or in journal publications).

#### Clinical Trial Sampling

We identified all trials registered on ClinicalTrials.gov in our three disease areas with a start date from 1 January 2009 to 31 December 2010 inclusive (eMethods 1 – search criteria). Our time range provided a minimum of nine years of follow-up for maturation toward trial completion and fulfillment of all four surrogates of informativeness. Trials were downloaded from ClinicalTrials.gov on 15 May 2020. We updated trial status and enrollment for all trials meeting our inclusion criteria on 6 October 2021.

We included randomized trials i) evaluating interventions of any type; ii) aimed at the treatment or prevention of ischemic heart disease, diabetes mellitus or lung cancer; iii) with at least one site in the United States (most of which will thus have a regulatory requirement for results reporting);<sup>12</sup> and iv) interventions that were FDA approved, that advanced to FDA approval, or interventions not subject to FDA approval (e.g. cardiac rehabilitation). We did not include trials that we deemed unlikely to be targeted at

informing clinical practice by excluding: i) studies that exclusively evaluated safety, diagnostic or screening interventions; and ii) early phase trials (phase 0 or phase 1) (eMethods 2 – inclusion/exclusion criteria; Figure 1 – flow diagram for trial inclusion; eMethods 3 – flow diagrams by disease; eMethods 4 – assessment of regulatory approval status). Phase 2 trials were included in our study as they are frequently used to inform both clinical and regulatory decision-making, particularly in cancer, where over one guarter of recent FDA cancer drug approvals were based on the results of phase 1/2 or phase 2 clinical trials. Trials were independently screened and assessed for eligibility by two authors (NH & HM), with disagreements resolved by a third reviewer (JK).

#### Figure 1. Flow Diagram for Trial Inclusion


174175

178

179

180

181



- a) Trials overlapping more than one disease area (for example, diabetes mellitus and ischemic heart disease) were allocated based on the disease evaluated in the primary outcome
- b) An indeterminate trial is an ongoing trial that has not surpassed twice the planned primary outcome completion date
- c) We used a random number generator (RAND function in Microsoft Excel) to create our 33% sample

Scoring Conditions of Informativeness

Two authors (NH & HM) independently scored all trials for the surrogate measures of the four conditions of informativeness (eTable 1; eMethods 5).

Disagreements were resolved by a third reviewer (JK). Because of their logical relationship among surrogate measures (e.g. citation in a high quality clinical synthesizing documents cannot be assessed unless trial results are available) and workflow (e.g. risk of bias information is often available in systematic reviews), conditions were scored sequentially. Trials not meeting one condition were not advanced for evaluation of subsequent conditions. The order of scoring was as follows: i) feasibility; ii) reporting; iii) importance; and iv) design. Trials meeting all four conditions were deemed informative; trials failing on any condition possessed features that compromised their informativeness.

Our assessments of informativeness began by evaluating feasibility based on timely trial completion and patient-participant recruitment success. Terminated trials were deemed infeasible if the reason for termination in the ClinicalTrials.gov registration record involved accrual, feasibility, funding or another non-scientific reason (as opposed to termination due to accumulated scientific data suggesting early efficacy, futility or toxicity) (eMethods 6 – classification of reason for termination). Completed trials were deemed to have not fulfilled feasibility if final participant enrollment was less than 85% of expected enrollment as listed in the final registration record prior to study start, thus reflecting a substantial loss of statistical power for the primary outcome. Trials that were ongoing were categorized as infeasible if they had already surpassed double the intended time for primary completion, which was

calculated by subtracting the intended primary completion date (as stated in the final registration record prior to study start) from the trial start date, then multiplying by two.

We next assessed results reporting by determining whether primary outcome results were publicly available. Trials were categorized as reported if they either had primary outcome results available on ClinicalTrials.gov or in a publication (eMethods 7 – methodology for publication search). When more than one publication presented primary outcome results, the earliest published report was identified and advanced to the next step of assessment. ClinicalTrials.gov results reporting and publication search were updated in October 2021 for those trials previously deemed to have not met the criteria for reporting.

Importance was scored by determining whether trial results were included in a high-quality review document designed to inform medical decision-making. To credit trials with being informative even if they produced negative results, trials were first assessed for inclusion in the results of a high-quality systematic review (SR), given that SR citation practices are results neutral. We assessed for trial results citation in a Cochrane SR, Agency for Healthcare Research and Quality (AHRQ) SR or in an SR deemed of high quality based on a modified AMSTAR score (eMethods 8 – SR search strategy and quality assessment). Trials not cited in the results of high-quality SRs were evaluated for inclusion in a high-quality CPG; remaining uncited trials were then assessed for inclusion in an UpToDate review article<sup>15</sup> (eMethods 9 – CPG search strategy, CPG quality assessment and point-of-care medical database search). Trials cited in high-quality review documents were deemed to have fulfilled the importance

condition. Assessment of importance was updated in October 2021 for all trials previously deemed to have not met the criterion for importance.

Finally, design was assessed by determining whether studies were at elevated risk of bias, using a modified Cochrane Risk of Bias (ROB) tool<sup>16</sup> (eMethods 10). When available, ROB scores were extracted directly from high-quality SRs identified during the assessment of trial importance. When unavailable, ROB scores were independently performed by two authors (NH & HM), with disagreements resolved by a third reviewer (JK). Trials were deemed to have fulfilled the design condition of informativeness if all ROB elements were deemed to be of low risk of bias, or a majority were low risk of bias with a minority of elements deemed to be of unclear risk of bias.

#### Statistical Analysis

Our primary outcome was the proportion of trials that met all four conditions of trial informativeness. We provided a 95% binomial confidence interval for our primary outcome. We performed a sensitivity analysis on our primary outcome excluding small, pilot-type studies that would not have been designed to inform clinical decision-making. These were identified based on an anticipated participant enrollment below the lowest quartile of target enrollment for our cohort of trials. Due to concern that phase 2 trials are less likely to inform clinical practice than trials of a higher phase, we performed a second sensitivity analysis on our primary outcome excluding phase 1/2 and phase 2 trials.

As secondary outcomes, we estimated the proportion of trial participants who were enrolled in informative trials, as well as the proportion of informative trials in each

of our three disease areas. We also report the proportion of trials advancing across each condition of informativeness. We provided 95% binomial confidence intervals for these secondary outcomes.

We compared the proportion of informative trials between disease categories and by trial sponsor using the Chi-square test (chisq.test function in R) and provided binomial confidence intervals for each stratum. We used the fisher test function in R to perform a two-sided Fisher's Exact test assessing the proportion of informative trials by type of intervention and trial phase and provided exact confidence intervals for each. We calculated inter-rater agreement rates using Cohen's kappa (eTable 2). We defined p < 0.05 as statistically significant. All analyses were performed using R version  $4.0.2.^{17}$ 

Our study was not subject to Institutional Review Board approval, as it relied on publicly accessible data. The study protocol was prospectively registered on Open Science Framework;<sup>18</sup> deviations and amendments to the study protocol are detailed in eMethods 11. The code<sup>19</sup> and data set<sup>18</sup> used in this analysis are available online. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines for cohort studies (eMethods 12).

#### Results

Over half of the 125 interventional trials in our cohort were studies of drug or biologic interventions (77 trials; 61.6%). The majority were Phase 2 (24 trials, 19.2%) or

- Phase 3 trials (50 trials, 40.0%). Trial status was "Completed" in 99 of 125 trials
- 278 (79.2%) and "Terminated" in 15 trials (12.0%) (Table 1).

#### **Table 1. Characteristics of Intervention Trial Cohort**

Category	Ischemic Heart Disease Trials N = 40	Diabetes Mellitus Trials N = 57	Lung Cancer Trials N = 28	All Trials N = 125 (%)
Trial Phase				
<b>2</b> <sup>a</sup>	6 (15.0)	5 (8.8)	13 (46.4)	24 (19.2)
3 <sup>b</sup>	11 (27.5)	26 (45.6)	13 (46.4)	50 (40.0)
4	10 (25.0)	9 (15.8)	0 (0.0)	19 (15.2)
NA	13 (32.5)	17 (29.8)	2 (7.1)	32 (25.6)
Intervention				
Drug/Biologic	19 (47.5)	34 (59.6)	24 (85.7)	77 (61.6)
Combination <sup>c</sup>	7 (17.5)	0 (0.0)	1 (3.6)	8 (6.4)
Device	4 (10.0)	4 (7.0)	0 (0.0)	8 (6.4)
Other <sup>d</sup>	10 (25.0)	19 (33.3)	3 (10.7)	32 (25.6)
Trial Status				
Completed	29 (72.5)	53 (93.0)	17 (60.7)	99 (79.2)
Terminated	7 (17.5)	1 (1.8)	7 (25.0)	15 (12.0)
Active, NR	0 (0.0)	1 (1.8)	4 (14.3)	5 (4.0)
Unknown	4 (10.0)	2 (3.5)	0 (0.0)	6 (4.8)
Outcome				
Clinical	24 (60.0)	8 (14.0)	10 (35.7)	42 (33.6)
Surrogate	16 (40.0)	49 (86.0)	18 (64.3)	83 (66.4)
Sponsore				
Industry	18 (45.0)	27 (47.4)	13 (46.4)	58 (46.4)
Other	22 (55.0)	30 (52.6)	15 (53.6)	67 (53.6)

<sup>&</sup>lt;sup>a</sup>Including Phase 1/2

blncluding Phase 2/3


<sup>°</sup>Including Drug + Device, Drug + Procedure, Behavioural + Device, Radiation Therapy + Drug

<sup>&</sup>lt;sup>d</sup>Including Behavioural Intervention, Radiation Therapy, Surgical Procedure, Cellular Intervention

<sup>&</sup>lt;sup>e</sup>As defined in ClinicalTrials.gov registration records


Our primary outcome, the proportion of trials that informed clinical practice, was 26.4% (95% CI 18.9 – 35.0) (Figure 2). As a sensitivity analysis, we re-analyzed our primary outcome excluding the 35 trials in the lowest quartile for target enrollment. This resulted in a proportion of informative trials of 35.6% (95% CI 25.7 – 46.3). We performed a second sensitivity analysis on our primary outcome excluding phase 1/2 and phase 2 trials. This resulted in 30.7% (95% CI 21.9 – 40.7) of trials meeting 4 conditions of informativeness.

Figure 2. Flow Diagram - The Proportion of Trials Meeting Four Conditions of Informativeness




A total of 193,839 participants were enrolled in the 125 trials in our cohort, of which 129,973 (67.1% (95% CI 66.8 – 67.3)) were enrolled in informative trials. The proportion of ischemic heart disease trials that was informative was 27.5% (95% CI 14.6 – 43.9); the proportion for diabetes mellitus trials was 31.6% (95% CI 19.9 – 45.2). and the proportion for lung cancer was 14.3% (95% CI 4.0 – 32.7) (Figure 3). Proportions did not vary significantly by disease area (p value = 0.23) (Figure 4). Each surrogate measure contributed considerably to the stepwise decline in the proportion of informative trials (eTable 3). Studies sponsored by industry were significantly more likely to fulfill all four conditions of informativeness than those not sponsored by industry (50.0% vs. 6.0%, p. value < 0.001)(Figure 4). Using the two-sided Fisher's exact test, there was a nonrandom association between trial phase and informativeness, and type of intervention and informativeness (Figure 4).

# Figure 3. The Cumulative Proportion of Trials Meeting Four Conditions of Informativeness by Disease Area



### Figure 4. The Proportion of Informative Trials by Trial Property



- A Proportion of Informative Trials by Phase (p-value =  $5.19 \times 10^{-5}$ )
- B Proportion of Informative Trials by Intervention Type (p-value = 0.02)
- C Proportion of Informative Trials by Disease Area (HD = Heart Disease) (p-value = 0.23)
- D Proportion of Informative Trials by Sponsor (p-value = 8.06 x 10<sup>-8</sup>)

#### **Discussion**

This study provides the first assessment of the proportion of randomized trials fulfilling four key conditions of informativeness. In our analysis, just over one fourth of trials demonstrated adequacy for study feasibility, reporting, importance, and design. The remaining 73.6% contained a limitation in design, conduct or reporting that compromised their ability to inform clinical decision-making.

Certain shortcomings of clinical trials are a result of experimenting in a dynamic real-world environment and cannot be entirely avoided. Clinical trials are difficult to plan, and there may be defensible reasons for falling short of some conditions. For example, changes in medical practice may render a research question irrelevant to clinical practice; an emerging viral pandemic might lead to under-recruitment. However, our findings underscore the major challenges sponsors and clinical investigators confront in fulfilling the scientific and ethical warrant for enrolling patient-participants in randomized trials. The goal should be to address foreseeable limitations in trial design, conduct or reporting. For example, increased oversight by research funders, including requirements for landscape analysis of completed and ongoing clinical trials to ensure trials are addressing important questions, and the provision of independent scientific review to highlight vulnerabilities in trial design, <sup>20</sup> are measures that can be implemented to increase the likelihood that trials will be informative. Many methodological weaknesses in trial design can be corrected at minor cost.<sup>8</sup>

The proportion of informative trials did not differ significantly between ischemic heart disease, diabetes mellitus and lung cancer, indicating shared challenges in design, implementation, and reporting. Our study also demonstrated that each

condition of informativeness goes unfulfilled in roughly equal proportions (eTable 2), suggesting that vigilance is required throughout the life cycle of a trial. Our estimates for the fraction of studies fulfilling criteria for recruitment feasibility are in line with prior studies. 14,21-23 The fraction of trials at low risk of bias is similar to prior estimates. 9,24,25 Our estimate for the fraction of studies fulfilling reporting requirements (90.0%) is in line with prior studies that evaluated both ClinicalTrials.gov results deposition and publication, 26,27 both of which were deemed acceptable means of results reporting in our study. To our knowledge, our study is the first to apply these conditions jointly to a sample of trials, in addition to assessing importance via citation in clinical synthesizing documents.

Our results also indicate that certain types of trials may be at greater risk for having their informativeness compromised. Phase 4 trials fared worse than Phase 3 trials, with only 2 of 19 fulfilling all 4 conditions of informativeness (eTable 4). Trials sponsored by industry funders were far more likely to fulfill all four conditions than those with non-industry sponsorship (50.0% vs. 6.0%). This is in keeping with prior research demonstrating greater recruitment challenges for non-industry funded trials, in addition to diminished compliance with timely results reporting on ClinicalTrials.gov. 28

These results suggest that funding bodies and academic medical centers may not provide adequate resources for fulfilling the clinical mission of the trials they support. Several recent initiatives aim at improving various aspects of informativeness, including increased consideration given to the importance and clinical relevance of the research question, the evidentiary basis for proposed research, study registration and

reporting, by many funders.<sup>29</sup> The implementation of new frameworks, such as INQUIRE, developed to guide academic institutions in addressing waste in research, including assessments of research design, feasibility, transparency, relevance, and internal and external validity, if widely adopted, may lead to further improvements in research quality.<sup>30</sup> The SARS-CoV-2 pandemic has highlighted both the susceptibility of our clinical research enterprise to substandard trials, while also showing what is possible with robust research vetting, coordination and collaboration.<sup>31</sup>

#### Limitations

Our study should be interpreted considering several limitations. First, our measures for each condition of informativeness are proxies for the concepts they represent. For example, scoring trial importance required citation in a clinical synthesizing document. This measure may have erroneously classified some informative trials as at risk of being uninformative (e.g. trials that evaluate disease management in niche populations that are not addressed in practice guidelines or systematic reviews). It may also have misclassified some trials as informative (e.g. trials addressing already resolved clinical hypotheses, which might nevertheless be cited in systematic reviews). To the former, none of the 18 trials not fulfilling the importance condition involved niche populations (eTable 5). We also acknowledge that some trials may inform clinical practice despite failing our criteria. The DAPT Study (NCT00977938) was a large Phase 4 study that was deemed at high risk of bias in several high-quality systematic reviews. 32,33 However, this study has had an important impact on the clinical management of antiplatelet therapy following drug-eluting stent placement. 34 Our

metrics are best understood as capturing factors that seriously (but not fatally) compromise a trial's prospects of informing practice, and that are rectifiable. Second, we applied strict inclusion/exclusion criteria when identifying out cohort of "clinically directed randomized controlled trials," thus limiting generalizability to other types of trials, including those involving diagnostics or interventions that do not advance to FDA approval. The latter would require different criteria, given their primary goal of informing regulatory decision-making. Third, we used a longitudinal approach, since conditions like publication or citation are only fulfilled after a study is completed. Changes in research practices or policy occurring over the last decade might produce different estimates for the proportion of randomized trials that are informative.

#### **Conclusions**

Trial volunteers are generally told that their participation will advance clinical practice. However, one third (33%) of patient-participants in our study were enrolled in trials that possessed at least one feature that compromised their goal of informing clinical practice. Sponsors and investigators often face unforeseeable challenges, and trials with flaws in design and implementation occasionally uncover actionable insights. Nevertheless, research systems and oversight should address persistent barriers to fulfilling the societal mission of clinical research.

#### **Bibliography**

- 1. Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. *The Lancet.* 2014;383(9912):156-165.
- Chan A-W, Song F, Vickers A, et al. Increasing value and reducing waste: addressing inaccessible research. *The Lancet.* 2014;383(9913):257-266.
- 453 3. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of 454 aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? 455 *Clin Trials.* 2005;2(3):218-229; discussion 229-232.
- 456 4. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. *The Lancet*. 2014;383(9913):267-276.
- 458 5. Ioannidis JPA, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. *The Lancet*. 2014;383(9912):166-175.
- Salman RA-S, Beller E, Kagan J, et al. Increasing value and reducing waste in biomedical research regulation and management. *The Lancet*.
   2014;383(9912):176-185.
- Yordanov Y, Dechartres A, Atal I, et al. Avoidable waste of research related to outcome planning and reporting in clinical trials. *BMC Med.* 2018;16(1):87.
- Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P.
   Avoidable waste of research related to inadequate methods in clinical trials.
   BMJ. 2015;350:h809.
- Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. *Nat Rev Drug Discov.* 2021;20(4):254-255.
- 471 10. Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical 472 Trials. *JAMA*. 2019;322(9):813-814.
- 11. London AJ, Kimmelman J. Against pandemic research exceptionalism. *Science*. 2020;368(6490):476-477.
- 475 12. U.S. Public Law 110-85 (Food and Drug Administration Amendments Act of
   476 2007), Title VIII, Section 801. (<a href="https://www.govinfo.gov/content/pkg/PLAW-477">https://www.govinfo.gov/content/pkg/PLAW-477</a>
   477 110publ85/pdf/PLAW-110publ85.pdf) Accessed 2020/07/24.
- Tibau A, Molto C, Ocana A, et al. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. *J Natl Cancer Inst.* 2018;110(5):486-492.

- 481 14. Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials.
- 483 *Clin Trials.* 2015;12(1):77-83.
- 484 15. UpToDate. (https://www.uptodate.com/home).
- Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
- 487 17. R Core Team. R: A language and environment for statistical computing. R
   488 Foundation for Statistical Computing, Vienna, Austria. 2013. <a href="http://R-project.org">http://R-project.org</a>.
- 489 18. What Fraction of Trials Inform Clinical Practice? A Longitudinal Cohort Study of
   490 Trials Registered on ClinicalTrials.gov. DOI 10.17605/OSF.IO/3EGKU.
   491 https://osf.io/3egku/.
- 492 19. <a href="https://codeberg.org/nhutchin/Informative\_Trials">https://codeberg.org/nhutchin/Informative\_Trials</a>.
- 493 20. Bierer BE, Strauss DH, White SA, Zarin DA. Universal Funder Responsibilities 494 That Advance Social Value. *Am J Bioeth.* 2018;18(11):30-32.
- Cheng SK, Dietrich MS, Dilts DM. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials. *Clin Cancer Res.* 2011;17(7):1947-1955.
- 498 22. Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National
   499 Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
   500 J Clin Oncol. 2010;28(35):5197-5201.
- Walters SJ, Bonacho Dos Anjos Henriques-Cadby I, Bortolami O, et al.
  Recruitment and retention of participants in randomised controlled trials: a
  review of trials funded and published by the United Kingdom Health Technology
  Assessment Programme. *BMJ Open.* 2017;7(3):e015276.
- Ndounga Diakou LA, Ntoumi F, Ravaud P, Boutron I. Avoidable waste related to inadequate methods and incomplete reporting of interventions: a systematic review of randomized trials performed in Sub-Saharan Africa. *Trials*. 2017;18(1):291.
- 509 25. Vale CL, Tierney JF, Burdett S. Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews. *BMJ*. 2013;346:f1798.
- 512 26. Chen R, Desai NR, Ross JS, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. *BMJ*. 2016;352:i637.

Phillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS. Association of 27. 515 the FDA Amendment Act with trial registration, publication, and outcome 516 517 reporting. Trials. 2017;18(1):333. 518 28. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report 519 clinical trial results on ClinicalTrials.gov: a cohort study. The Lancet. 520 2020;395(10221):361-369. Moher D, Glasziou P, Chalmers I, et al. Increasing value and reducing waste in 521 29. 522 biomedical research: who's listening? The Lancet. 2016;387(10027):1573-1586. von Niederhausern B, Guyatt GH, Briel M, Pauli-Magnus C. Academic response 523 30. to improving value and reducing waste: A comprehensive framework for 524 INcreasing Quality In patient-oriented academic clinical REsearch (INQUIRE). 525 526 PLoS Med. 2018;15(6):e1002580. 527 31. Kimmel SE, Califf RM, Dean NE, Goodman SN, Ogburn EL. COVID-19 Clinical 528 Trials: A Teachable Moment for Improving Our Research Infrastructure and 529 Relevance. Ann Intern Med. 2020;173(8):652-653. Xu Y, Shen Y, Chen D, Zhao P, Jiang J. Efficacy and Safety of Dual Antiplatelet 530 32. 531 Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis. J Interv Cardiol. 2021;2021:9934535. 532 Yin SH, Xu P, Wang B, et al. Duration of dual antiplatelet therapy after 533 33. 534 percutaneous coronary intervention with drug-eluting stent: systematic review 535 and network meta-analysis. BMJ. 2019;365:l2222.

Cutlip DE, Nicolau JC. Long-term antiplatelet therapy after coronary artery

stenting in stable patients In: UpToDate, Dardas TF (Ed), UpToDate, Waltham,

536

537

538

539 540 34.

MA.

541 Supplementary Material 542 543 eMethods 1 - ClinicalTrials.gov search criteria eMethods 2 - Trial Inclusion and Exclusion criteria 544 eMethods 3 - Flow Diagrams for Each Disease 545 eMethods 4 – Assessment of Regulatory Approval Status 546 547 eTable 1 – Addressing 4 Conditions for Informative Clinical Trials 548 eMethods 5 - Flow Chart of Informative Criteria Assessment 549 eMethods 6 - Classification of Reason for Termination 550 eMethods 7 - Methodology for Publication Search eMethods 8 - Systematic Review Citation Search Strategy and Quality Assessment 551 eMethods 9 - Clinical Practice Guideline and Point-of-Care Medical Database Search 552 Strategies and Quality Assessment 553 554 eMethods 10 - Operationalization of modified Cochrane Risk of Bias score eMethods 11 – Deviations to the Study Protocol 555 556 eMethods 12 – STROBE Checklist for Cohort Studies 557 eTable 2 – Inter-rater Agreement Rates 558 eTable 3 - Proportion of Trials Meeting Each Criterion for Informativeness eTable 4 - Phase 4 Trials Not Meeting 4 Informativeness Criteria 559 eTable 5 - Trials Not Cited in Clinical Review Documents 560 561 562 563

eMethods 1 - ClinicalTrials.gov search criteria

1. Condition or disease search terms:

564565566

567

568

569 570

571

572573

574575576

577578

579

580

581 582 583

- a) ISCHEMIC HEART DISEASE: coronary artery disease OR coronary disease OR coronary heart disease OR coronary occlusion OR acute coronary syndrome OR myocardial ischemia OR angina pectoris OR angina, stable OR angina, unstable OR myocardial infarction OR ischemic heart disease
- b) LUNG CANCER: Lung cancer OR lung neoplasm OR lung carcinoma OR nonsmall-cell lung cancer OR non-small-cell lung carcinoma OR small cell lung cancer OR small cell lung carcinoma OR lung tumor OR lung tumour
- c) DIABETES: diabetes mellitus OR diabetes
- 2. Study type: "Interventional Studies (Clinical Trials)"
  - 3. Recruitment status: "Recruiting, Completed, Suspended, Terminated, Active not recruiting, enrolling by invitation and unknown status"
- 4. Study start: 2009-01-01 to 2010-12-31

eMethods 2 - Trial Inclusion and Exclusion criteria

#### Inclusion criteria:

586 587 588

605 606

607

- -Primary outcome = clinical decision-related outcome: including mortality, morbidity,
- 590 quality of life, functional status, need for further interventions, or an appropriate
- 591 surrogate measures (for example, ejection fraction, Hgb A1c, or progression free
- 592 survival in ischemic heart disease, diabetes mellitus and lung cancer respectively)
- -Intervention of any type (drug, device, behavioral, surgical or other) directed towards
- the treatment or prevention of ischemic heart disease/lung cancer/diabetes mellitus
- 595 (and not side-effects of the disease or complications from disease treatment)
- 596 -Trials with a US site
- 597 -Randomized trials
- 598 -Multi-arm trials
- -Trials of interventions subject to FDA regulations and are FDA approved prior to trial start
- 601 -Trials of interventions not subject to FDA regulations
- -Trials of interventions subject to FDA regulations, FDA approved post trial start, and
- have at least 5 years of follow-up since FDA approval, to allow for ample time for
- results incorporation into systematic reviews/clinical practice guidelines/UpToDate

#### Exclusion criteria:

- -Exclusively evaluating safety, diagnostic or screening interventions
- 608 -Exclusion of phase 0 or phase 1 trials (given these early phase trials would be unlikely to inform clinical decision-making)
- -Exclusion of extension studies with primary aim to enable continued access to drug (and without additional post-marketing surveillance outcomes)
- -Indeterminate trials, which are ongoing trials have not surpassed double the allotted
   time for primary outcome completion (as first stated in the historical clinicaltrials.gov
   registration record)


#### eMethods 3 - Flow Diagrams for Each Disease

631


632

675

Flow Diagram for Ischemic Heart Disease Interventional Trials




a) An indeterminate trial is an ongoing trial that has not surpassed twice the planned primary outcome completion date



a) We used a random number generator (RAND function in Microsoft Excel) to create our 33% sample

## Flow Diagram for Lung Cancer Interventional Trials



#### eMethods 4 – Assessment of Regulatory Approval Status


Two authors (NH & HM) independently evaluated all eligible trials for regulatory approval status using Drugs@FDA¹ for drug and biological interventions and the 510(k) Premarket Notification website for devices.² Interventions were classified into one of 3 categories: i) FDA approved prior to trial start (drug, biological or device interventions approved for any use by the time of trial start); ii) FDA approved at least 5 years ago ((drug, biological or device interventions approved for any use prior to October 31, 2016); and, iii) interventions not subject to FDA approval.

## eTable 1 - Addressing the 4 Conditions for Informative Clinical Trials

Conditions for Informativeness <sup>1</sup>	Manner in which this is evaluated
Importance: Trial hypothesis is likely to inform an important scientific, medical or policy question	-Trials are selected for inclusion in our cohort based on their potential to inform clinical decision-making, based on presence of a primary clinical outcome or appropriate surrogate.  -We also assess importance by evaluating the proportion of trials that are cited in clinical review documents (systematic reviews, clinical practice guidelines or point-of-care medical database articles).
Design: Trial methods are likely to provide meaningful evidence related to study hypothesis	-We assess trials that are designed to inform clinical decision-making for evidence of low risk of bias
Feasibility: Trial is likely to be feasible	-Feasible trials include:  -Completed trials that have reached ≥ 85% planned recruitment  -Terminated trials stopped for an informative reason (such as efficacy, futility or safety)  -Ongoing trials that have not surpassed double their anticipated primary completion timeline
Reporting: Systems are in place to ensure timely, complete and accurate reporting	-A trial is reported if primary outcome results are made available through publication or results deposition on ClinicalTrials.gov

<sup>&</sup>lt;sup>1</sup>Column "Conditions for Informativeness" extracted from column1 in eTable 1<sup>3</sup>

#### eMethods 5 - Flow Chart of Informative Criteria Asses



## eMethods 6 - Classification of Reason for Termination

NCT	Reason for Termination	Outcome
NCT00831441	None Provided	Advanced to next step of assessment
NCT00863512	None Provided	Advanced to next step of assessment
NCT00887315	Accrual; Loss of sponsor	Infeasible
NCT00910299	Futility	Advanced to next step of assessment
NCT00932152	Accrual	Infeasible
NCT00965055	Accrual	Infeasible
NCT01041781	DSMB Recommendation	Advanced to next step of assessment
NCT01078272	Accrual	Infeasible
NCT01246011	Accrual	Infeasible
NCT00976677	None Provided	Advanced to next step of assessment
NCT01177592	Funding	Infeasible
NCT01179308	PI closed study site	Infeasible
NCT01197963	IRB Decision	Advanced to next step of assessment
NCT01231750	Accrual	Infeasible
NCT01413750	Accrual	Infeasible

#### eMethods 7 – Methodology for Publication Search

 The search for publications was independently performed by two authors (NH & HM) and included an evaluation of publication links provided on ClinicalTrials.gov, as well as directed searches on Google Scholar, Scopus and Medline using a combination of the unique trial registration number (NCT number), surname of the principal investigator, indication, intervention, phase and study design. Publication identity was confirmed by comparing trial arms, sample size, intervention details, comparators and sponsor with the registration record. A published abstract was not counted as a full publication. Publication search was repeated in October 2021 by NH & HM for those trials without publications when first assessed.

## eMethods 8 – Systematic Review Citation Search Strategy and Quality Assessment

Assessment of citation of trial results in high quality systematic reviews (SRs) was independently performed by two authors (NH & HM). This first involved a search for sources that are well known for producing high quality SRs: Cochrane SRs on the Cochrane Database of Systematic Reviews<sup>4</sup> and Agency for Healthcare Research and Quality (AHRQ) SRs <sup>5</sup>. If trials were not included in Cochrane or AHRQ reviews, additional SRs for published studies were identified using the Scopus database <sup>6</sup> citation analysis search function or via Google Scholar <sup>7</sup> for unpublished studies. SRs identified through Scopus or Google Scholar that included trial results in review results were assessed for quality using a modified AMSTAR scoring system:

Operationalization of modified AMSTAR<sup>8,9</sup> scoring system

-  -	<b>-</b>		
1.	Was an "a priori" design provided?  Yes – the authors stated that methods were established prior to conducting the review or provided a link to a registered protocol record		
		No – the authors stated that there's no protocol available or no information is provided	
2.	Was there duplicate study selection and data extraction?		
		Yes – at least two individuals independently performed study selection and data extraction; the method for reaching consensus in the setting of disagreement was reported	
		No – only one person performed either study selection or data extraction	answer (0)
		Can't answer – no information about independent study selection and/or data extraction was provided	
3.	Was a comprehensive literature search performed?		
		Yes – at least two electronic sources were searched; keywords or MESH terms were provided	
		No – only one database was searched; no keywords or MESH terms were provided	□ Can't answer (0)
		Can't answer – partial or no information reported	
	4.	Was a list of studies (included and excluded) provided?	□ Yes (1)

	Yes - a list of included and excluded studies was provided	□ No (0)		
	No – a list of included and excluded studies was not provided			
5.	Was the scientific quality of the included studies assessed			
	and documented with a study-specific quality score provided? Yes – risk of bias or another quality metric was used and reported	□ No (0)		
	No – no risk of bias or quality metric was used	□ Can't answer		
	Can't answer – the authors state that a quality metric was done, but do not provide additional information	(0)		
High qua	ality review = score of ≥ 3/5			
results	vere deemed to have fulfilled the importance criterion if they were citor of a Cochrane SR, an AHRQ SR, or an SR achieving a modified AM ter or equal to 3 out of 5.			
Assessment of citation of trial results in SRs was repeated in October 2021 by NH & HM for those trials without an informative citation when first assessed.				

### eMethods 9 - Clinical Practice Guideline and Point-of-Care Medical Database **Search Strategies and Quality Assessment**

Assessment of citation of trial results in Clinical Practice Guidelines (CPGs) was independently performed by two authors (NH & HM). CPGs were identified via Scopus <sup>6</sup> citation analysis for published studies or via Google Scholar <sup>7</sup> for unpublished trials. Quality of CPGs was assessed using a modified AGREE II scoring system:

836 837

838 839

840

841

Оре	rat	tionalization of modified AGREE II 10 scoring system			
	1.	Were systematic methods used to search for evidence and criteria for selection of evidence clearly described?			
		Yes – the authors described electronic databases/sources where search was performed, time periods searched, key terms used; inclusion/exclusion criteria for evidence selection were outlined			
		No – no description was available/no systematic search for evidence conducted/no criteria for selection of evidence described			
	2.	Were the strengths and limitations of the body of evidence	□ Yes (1)		
		clearly described?	□ No (0)		
		Yes – description of the tools used to assess quality of evidence provided (e.g. GRADE framework) or explicit discussion of the quality of the entire group of included trials provided			
		No – no evaluation of quality			
	3.	Were the methods for formulating recommendations clearly	□ Yes (1)		
		described?			
		Yes – description of the recommendation development process was included (e.g. voting procedures) and level of consensus reached were described			
		No – no clear description of the process involved in formulating recommendations provided			
	4.	Were the guidelines externally reviewed prior to publication?	□ Yes (1)		

	Yes – guidelines were externally reviewed and reviewers were not involved in the guideline development group  No – no external review performed or reviewers not independent of guideline information  Can't answer – insufficient information to evaluate external review process	□ Can't answer (0)		
5.	Were competing interests of guideline developers recorded and addressed?			
	Yes – a description of competing interests was provided and their potential impact on guideline development discussed; guideline developers were independent from funding body / funding body did not influence final recommendations			
	No – no competing interests described, or impact on guideline development not assessed, or unclear if funding body has influenced guideline development			

High quality review = score of  $\geq 3/5$ 

Trials were deemed to have fulfilled criteria for importance if they were cited in the results of a high-quality CPG. The remaining uncited trials were assessed for inclusion in a point-of-care medical database article by two authors (NH & HM). Using disease and intervention keywords, we searched UpToDate<sup>11</sup> to identify any articles citing the remaining trials.

Assessment of citation of trial results in Clinical Practice Guidelines (CPGs) was repeated in October 2021 by NH & HM for those trials without an informative citation when first assessed.

#### eMethods 10 - Operationalization of modified Cochrane Risk of Bias score

 We employed a modified 2011 version of the Cochrane Risk of Bias Assessment Tool (detailed criteria for judging risk of bias provided in Table 8.5d of the Cochrane Handbook for Systematic Reviews of Interventions version 5.1) <sup>12</sup>. When available, ROB scores were extracted directly from high-quality SRs identified during the assessment of trial importance. When not available, assessment was independently carried out by two authors (NH & HM), with differences resolved by a third (JK). Assessment included the following elements: i) random sequence generation; ii) allocation concealment; iii) blinding of participants and personnel; iv) blinding of outcome assessment; v) incomplete outcome data; and, vi) selective reporting. Trials were deemed of sufficient design quality if all elements were deemed to be "low risk of bias" or if a minority of elements were deemed of "unclear risk" and the remaining were "low risk." Any "high risk" of bias element equated with poor trial design.

Of the 63 trials assessed for trial design, 36 ROB scores were extracted directly from SRs, the remaining 27 trials were assessed by the study team.

#### eMethods 11 - Deviations to the Study Protocol

- 1. For our feasibility assessment, we first evaluated feasibility of goal patient enrollment and planned date of primary completion based on the first record available on ClinicalTrials.gov (this was independently double-coded). However, we repeated this assessment using the final registration record prior to trial start date as this was felt to provide a better evaluation of feasibility, allowing investigators to adjust enrollment plans and primary outcome timeline prior to trial start. The latter method was single coded and did not produce any change in the results of our feasibility assessment.
- 2. We performed two additional sensitivity analyses on the primary outcome: i) excluding all trials in the lower quartile of goal patient enrollment; and, ii) excluding all phase 1/2 and phase 2 trials from the assessment.
- 3. We excluded evaluation of primary outcome integrity from our assessment of trial informativeness, given concerns that there can be scientifically valid reasons for altering a primary outcome. For example, a primary outcome might be changed due to evolving clinical practice or in response to new data from outside the trial.
- 4. We excluded trials of interventions that were subject to FDA regulations, but were never approved for any indication, or were FDA approved after trial start, but did not have 5 years of follow-up time from 31 October 31 2016 post-approval to allow for enough time for trial results to be included in systematic reviews/clinical practice guidelines/UpToDate.
- 5. We excluded Indeterminate trials from our cohort, defined as ongoing trials that have not surpassed double the allotted time for primary outcome completion (as first stated in the historical clinicaltrials.gov registration record)

#### eMethods 12 - STROBE Checklist for Cohort Studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the	1
The and abstract	•	title or the abstract	'
		(b) Provide in the abstract an informative and balanced summary of	2
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	3
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including	4-5
		periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	5-6
		selection of participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of	
Veriables	7	exposed and unexposed	0.10
Variables	1	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if	8-10
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	8-10
measurement	O	methods of assessment (measurement). Describe comparability of	0 10
THOUSEN STITE THE		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10
Study size	10	Explain how the study size was arrived at	Figure1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	10-11
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control	10-11
		for confounding	
		(b) Describe any methods used to examine subgroups and	
		interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	Figure1
		numbers potentially eligible, examined for eligibility, confirmed	7
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	Table1
		clinical, social) and information on exposures and potential confounders	11-12
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg. average and total amount)	
Outcome data	15*	(c) Summarise follow-up time (eg, average and total amount)  Report numbers of outcome events or summary measures over	13

909

910 911 912 Main results (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates 13and their precision (eg, 95% confidence interval). Make clear which confounders 14 were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Other analyses Report other analyses done—eg analyses of subgroups and interactions, and 13sensitivity analyses 14 **Discussion** Key results 18 Summarise key results with reference to study objectives 17 Limitations Discuss limitations of the study, taking into account sources of potential bias or 19imprecision. Discuss both direction and magnitude of any potential bias 20 Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 17multiplicity of analyses, results from similar studies, and other relevant evidence 20 21 Discuss the generalisability (external validity) of the study results 20 Generalisability Other information Give the source of funding and the role of the funders for the present study and, if 2 **Funding** 22 applicable, for the original study on which the present article is based

## eTable 2 - Inter-rater Agreement Rates

Category	Unweighted Cohen's Kappa			
Screening trials for inclusion/exclusion	0.83			
Evaluating trial Feasibility	0.98			
Evaluating trial Reporting	0.79			
Evaluating trial Importance	0.67			
Evaluating trial Design	0.84			

# eTable 3 - Proportion of Trials Meeting Each Criterion for Informativeness

Condition for Informativeness	Ratio	% (95% CI)
Feasibility	90 of 125 trials	72.0 (63.3 – 79.7)
Reporting	81 of 90 trials	90.0 (81.9 – 95.3)
Importance	63 of 81 trials	77.8 (67.2 – 86.3)
Design	33 of 63 trials	52.4 (39.4 – 65.1)

## eTable 4 - Phase 4 Trials Not Meeting All 4 Informativeness Criteria

NCT	Disease	Title	Trial Status	Sponsor	Informativeness Assessment
NCT00954707	IHD	A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)	Unknown (Previously, Active, NR)	Industry	Not cited in review documents
NCT00977938	IHD	A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions	Completed	Non- Industry	Elevated Risk of Bias Score
NCT01050348	IHD	A Double Blinded Randomized Placebo Controlled Study: To Investigate the Role of Upstream High Dose Statin Treatment in Patients With ST Segment Elevation Myocardial Infarction	Completed	Non- Industry	Not Reported
NCT01069003	IHD	EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy Drug Regimen	Completed	Industry	Elevated Risk of Bias Score
NCT01106534	IHD	XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT)	Completed	Industry	Poor Feasibility
NCT01178268	IHD	XIENCE V Everolimus Eluting Coronary Stent System China: Post-Approval Randomized Control Trial	Completed	Industry	Not cited in review documents
NCT01221272	IHD	A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging	Completed	Industry	Poor Feasibility
NCT01230892	IHD	The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease	Completed	Non- Industry	Not cited in review documents

NCT01246011	IHD	Significance of Antibodies to	Terminated	Non-	Poor Feasibility
		Heparin/Platelet Factor 4 Complex in		Industry	,
		Vein Graft Patency and Potential Role of		·	
		Argatroban for Prevention of Vein Graft			
		Occlusion			
NCT01101867	DM	Prandial Insulin Dosing Using the	Completed	Non-	Not cited in
		Carbohydrate Counting Technique in		Industry	review
		Hospitalized Patients With Diabetes			documents
NCT01267448	DM	A Pilot Study of Outpatient Discharge	Unknown	Non-	Poor Feasibility
		Therapy With Saxagliptin + Metformin	(Previously,	Industry	
		XR or Sulphonylurea for Recently	Recruiting)		
		Diagnosed Type 2 Diabetes Presenting			
		With Severe Hyperglycemia			
NCT00978796	DM	Pilot Study Assessing Glucose Effects	Completed	Non-	Not cited in
		of Sitagliptin (Januvia) in Adult Patients		Industry	review
		With Type 1 Diabetes			documents
NCT00979628	DM	Basal Bolus Versus Basal Insulin	Completed	Non-	Elevated Risk of
		Regimen for the Treatment of		Industry	Bias Score
		Hospitalized Patients With Type 2			
NOTO4407747	- DM	Diabetes Mellitus	A at' a ND	NI.	D E % . %
NCT01107717	DM	Durability of Early Initial Combination	Active, NR	Non-	Poor Feasibility
		Therapy With		Industry	
		Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset			
		Type 2 Diabetes			
NCT00939250	DM	A Comprehensive Intervention for	Completed	Non-	Poor Feasibility
140100939230	DIVI	Diabetes and Comorbid Depression in	Completed	Industry	1 001 1 easibility
		Primary Care		industry	
NCT00950677	DM	The Effect of the Glucagon Suppressors	Completed	Non-	Not Reported
11010000011	Divi	Pramlintide and Exenatide on	Completed	Industry	rtotrioportod
		Postprandial Glucose Metabolism in			
		Children With Type 2 Diabetes Mellitus			
NCT01221090	DM	Employing Diabetes Self-Management	Completed	Non-	Elevated Risk of
		Models to Reduce Health Disparities in	•	Industry	Bias Score
		Texas		•	

IHD - Ischemic Heart Disease

DM - Diabetes Mellitus

### eTable 5 - Trials Not Cited in Clinical Review Documents

NCT	Disease	Title	Phase	Trial Status	Sponsor	Published Results
NCT00924118	IHD	A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Prevention of Ischemia- Reperfusion Injury Associated with Acute Myocardial Infarction	2	Completed	Non- Industry	NO
NCT00954707	IHD	A Prospective, Randomized, Multi- Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER Sirolimus-eluting Coronary Stent	4	Unknown (Previously, Active, Not Recruiting)	Industry	NO
NCT01175018	IHD	Anakinra to Prevent Adverse Post- infarction Remodeling	2	Completed	Non- Industry	YES
NCT01178268	IHD	XIENCE V Everolimus Eluting Coronary Stent System China: Post-Approval Randomized Control Trial	4	Completed	Industry	NO
NCT01230892	IHD	The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease	4	Completed	Non- Industry	YES
NCT01101867	DM	Prandial Insulin Dosing Using the Carbohydrate Counting Technique in Hospitalized Patients With Diabetes	4	Completed	Non- Industry	YES
NCT01194245	DM	A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro- PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog) in Patients With Type 1 Diabetes	2	Completed	Industry	NO
NCT00916357	DM	Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM	2	Completed	Industry	YES
NCT00993824	DM	Use of Continuous Glucose Monitoring With Ambulatory	2/3	Completed	Non- Industry	YES

		Chicago Profile Analysis to				
		Glucose Profile Analysis to Demonstrate the Glycemic Effect of				
		Colesevelam HCI (Welchol) in				
		Patients With Type 2 Diabetes				
NCT00918138	DM	A 4-Week, Multicenter,	3	Completed	Industry	YES
10000000000	DIVI	Randomized, Double-Blind, Phase	3	Completed	industry	11.5
		3b Trial to Evaluate the Efficacy of				
		Saxagliptin in Combination With				
		Metformin XR 1500 mg Versus Up-				
		titrated Metformin XR to 2000 mg				
		in Subjects With Type 2 Diabetes				
		Who Have Inadequate Glycemic				
		Control With Diet and Exercise and				
		a Stable Dose of Metformin XR				
		1500 mg				
NCT00844090	DM	The Role of Apathy in Glycemic	NA	Completed	Non-	NO
1401000++000	DIVI	Control	14/ (	Completed	Industry	110
NCT00978796	DM	Pilot Study Assessing Glucose	4	Completed	Non-	YES
110100010100	5	Effects of Sitagliptin (Januvia) in	•	Completed	Industry	. 20
		Adult Patients With Type 1			ii iddoii y	
		Diabetes				
NCT01089569	DM	Evaluation of Insulin Glargine and	NA	Completed	Non-	YES
		Exenatide: A Randomized Clinical		'	Industry	
		Trial with Continuous Glucose				
		Monitoring and Ambulatory				
		Glucose Profile Analysis				
NCT00918203	Lung	A Randomized Phase 2 Study of	2	Completed	Industry	YES
	CA	Human Anti-PDGFRa Monoclonal				
		Antibody (IMC-3G3) with				
		Paclitaxel/Carboplatin or				
		Paclitaxel/Carboplatin Alone in				
		Previously Untreated Patients with				
		Locally Advanced or Metastatic				
NOTOGOZOGZZ		Non-Small Cell Lung Cancer	•			NO
NCT00976677	Lung	Randomized Double-Blind Placebo	2	Terminated	Non-	NO
	CA	Controlled Phase II Trial Evaluating			Industry	
		Erlotinib in Non-Smoking Patients				
		With (Bevacizumab-Eligible and				
		Ineligible) Advanced Non-Small				
NCT00977470	Lung	Cell Lung Cancer Phase II Study of Erlotinib With or	2	Active, NR	Non-	NO
140100311410	CA	Without Hydroxychloroquine in	_	ACTIVE, INIT	Industry	INO
	<i>5</i> , (	Patients With Previously Untreated			aasti y	
		Advanced NSCLC and EGFR				
		Mutations				
NCT01085136	Lung	Phase III Randomized Trial of BIBW	3	Completed	Industry	YES
	CA	2992 Plus Weekly Paclitaxel Versus			<b>,</b>	
		Investigator's Choice of				
		Chemotherapy Following BIBW				
		2992 Monotherapy in Non-Small				
		Cell Lung Cancer Patients Failing				
		Previous Erlotinib or Gefitinib				
		Treatment (LUX Lung 5)				

NCT01104155	Lung CA	Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated, Advanced Non-Small Cell Lung Cancer	2	Completed	Industry	YES
-------------	------------	---	---	-----------	----------	-----

IHD - Ischemic Heart Disease

DM - Diabetes Mellitus

929

930

931

Lung CA - Lung Cancer

**Supplementary Bibliography** 932 933 934 1. Drugs@FDA https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. 510(k) Premarket Notification 935 2. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. 936 937 3. Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical 938 Trials. JAMA. 2019;322(9):813-814. 939 4. Cochrane Database of Systematic Reviews. (https://www.cochranelibrary.com/cdsr/reviews) 940 941 5. Agency for Healthcare Research and Quality. (https://effectivehealthcare.ahrg.gov). 942 6. Scopus. (https://www.scopus.com) 943 7. Google Scholar. (https://scholar.google.ca). 944 945 8. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin 946 Epidemiol. 2009;62(10):1013-1020. 947 948 9. Flodgren G, Eccles MP, Shepperd S, Scott A, Parmelli E, Beyer FR. An overview 949 of reviews evaluating the effectiveness of financial incentives in changing 950 healthcare professional behaviours and patient outcomes. Cochrane Database Syst Rev. 2011(7):CD009255. 951 10. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline 952 development, reporting and evaluation in health care. CMAJ. 953 2010;182(18):E839-842. 954 UpToDate. (https://www.uptodate.com/home). 955 11. The Cochrane Collaboration, Cochrane Handbook for Systematic Reviews of 956 12. 957 Interventions version 5.1.0. Eds J.P.T. Higgins & S.Green. 2011. 958 https://training.cochrane.org/handbook/archive/v5.1/. 959 960 961